Edesa Biotech's Paridiprubart Shows 27% Mortality Reduction in Phase 3 ARDS Study
核心洞察
Edesa Biotech's anti-TLR4 (搜索) antibody paridiprubart demonstrated a statistically significant 27% relative reduction in 28-day mortality risk in a Phase 3 study of 278 ARDS (搜索) patients.
The treatment reduced adjusted mortality from 33% to 24% across the full population and showed consistent benefits in patients with serious comorbidities including sepsis (搜索), pneumonia (搜索), and acute kidney injury (搜索).
Based on these results, Edesa has filed provisional patent applications for paridiprubart's use in treating sepsis (搜索), acute kidney injury (搜索), and pneumonia (搜索) while advancing regulatory discussions and partnership opportunities.
Edesa Biotech announced positive additional data from its Phase 3 study of paridiprubart, a first-in-class anti-TLR4 (搜索) antibody, demonstrating a statistically significant reduction in 28-day mortality among patients with acute respiratory distress syndrome (ARDS (搜索)). The results encompass a broader 278-patient population, including both previously reported 104 patients requiring invasive mechanical ventilation (IMV) and 174 non-IMV patients.
Primary Endpoint Achievement
The primary endpoint was achieved for the full treatment population of 278 randomized subjects. Paridiprubart reduced adjusted 28-day mortality to 24% from 33%, representing a 27% relative reduction in the risk of death (p<0.001). Subjects receiving paridiprubart also demonstrated a higher relative rate of clinical improvement by Day 28 compared to placebo. All patients received paridiprubart or placebo in addition to standard of care treatments.
Efficacy Across Patient Subgroups
In an exploratory analysis of 174 randomized patients who did not meet the study's IMV-based inclusion criteria, paridiprubart plus standard of care reduced adjusted 28-day mortality to 15% from 23% (placebo plus standard of care), achieving a 35% relative reduction in the risk of death (p<0.05).
Exploratory analyses across patient populations of up to 108 randomized subjects consistently demonstrated reduced adjusted mortality for paridiprubart plus standard of care versus placebo plus standard of care at 28 days in subjects with clinically important comorbidities:
- Acute Kidney Injury: 35% relative reduction (35% paridiprubart vs. 53% placebo; p<0.05, n=48)
- Sepsis: 36% relative reduction (40% paridiprubart vs. 63% placebo; p<0.05, n=41)
- Pneumonia: 30% relative reduction (35% paridiprubart vs. 49% placebo; p<0.05, n=108)
Safety Profile
Overall rates of adverse events, serious adverse events, infections and treatment discontinuations were low and similar between the paridiprubart and placebo groups. The safety profile was consistent with prior clinical exposures, with more than 400 patients now having received paridiprubart.
Regulatory and Commercial Strategy
Based on these positive results, Edesa has filed provisional patent applications with the United States Patent and Trademark Office covering the use of paridiprubart in the treatment of sepsis (搜索), acute kidney injury (搜索) and pneumonia (搜索). The company's core composition-of-matter patents extend into the 2030s.
"The consistency of mortality reduction and clinical improvement across all 278 randomized patients, including less severe patients as well as those with ARDS (搜索) complicated by acute kidney injury (搜索), sepsis (搜索) and pneumonia (搜索), underscores the versatility and transformative potential of paridiprubart to address multiple critical unmet medical needs," said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. "We are advancing regulatory discussions and evaluating strategic collaborations and partnership opportunities that could accelerate development and broaden global access."
Ongoing Development
Paridiprubart is currently being evaluated in a separate U.S. government-funded study of ARDS (搜索) patients, with enrollment ongoing for up to approximately 200 randomized subjects for the Edesa cohort. The company's paridiprubart development program, including manufacturing scale-up, late-stage development and commercial readiness, also receives funding from the Government of Canada.
Study Methodology
Data were derived from the full study safety population of 278 patients, with the previously reported 104-patient IMV ITT cohort representing a prespecified subset. Patients were randomly assigned (1:1) to standard of care with paridiprubart (n=138) or standard of care with placebo (n=140). All prespecified efficacy evaluations were conducted using an identical multivariate logistic regression model with the same covariates, managed by JSS Medical Research.
About the Mechanism
Paridiprubart represents a new class of host directed therapeutics designed to modulate the body's immune response. The drug inhibits toll-like receptor 4 (TLR4 (搜索)), a key immune signaling protein activated by viruses, bacteria, injury/trauma and in the pathogenesis of chronic autoimmune diseases. Dr. Nijhawan noted that the results align with the central role of TLR4 in hyperinflammatory ARDS (搜索) and demonstrate consistent benefit across high-mortality etiologies.
Edesa has been selected for an oral presentation at the American Thoracic Society 2026 International Conference and plans to present additional findings from its Phase 3 study at other upcoming medical and scientific conferences.